Earnings Call · Q1 FY2022·2022-05-09

Q1 22EPS -13.64%·Rev n/aQ4 21EPS +78.26%·Rev n/aQ3 21EPS -7.69%·Rev n/aQ2 21EPS -38.10%·Rev n/a⚠ consensus missing

OCULAR THERAPEUTIX, INC OCUL

Donald Notman — Chief Financial Officer

Antony Mattessich — Chief Executive Officer

Michael Goldstein — Senior Vice President, Research and Development

−6.1%1d on move date−2.9% vs SPY3d−11.2%5d−5.5%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more OCUL calls or request research access.

More OCUL calls Browse calls Request research access